Web17 feb 2024 · Granix: tbo-filgrastim 300 mcg/0.5 mL (0.5 mL); tbo-filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80] Pharmacology Mechanism of Action Filgrastim is a granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. WebTbo-filgrastim (filgrastim XM02; Biograstim(®), Ratiograstim(®), Tevagrastim(®)) is approved in the EU as a biosimilar of filgrastim (Neupogen(®)) for use in all indications for which reference filgrastim is approved, including chemotherapy-induced neutropenia, neutropenia in patients undergoing myeloablative therapy followed by bone marrow …

Teva Announces Updated Indication and Vial Presentation for …

WebGranix (tbo-filgrastim) is a member of the colony stimulating factors drug class and is commonly used for Neutropenia Associated with Chemotherapy. The cost for Granix subcutaneous solution (300 mcg/0.5 mL) is around $273 for a supply of 0.5 milliliters, depending on the pharmacy you visit. Webtbo-filgrastim (Granix): Orphan designation for mobilization of peripheral blood progenitor cells (PBPCs) in healthy donors prior to allogeneic PBPC transplantation Sponsors … ptp accounting tv

Tbo-Filgrastim (Granix) National Drug Monograph - December 2014

Web31 mar 2024 · Tbo-filgrastim injection is used to treat severe neutropenia (low white blood cells) that is caused by cancer medicines. It is a synthetic (man-made) form of a substance that is naturally produced in the body called a colony stimulating factor. Tbo-filgrastim helps the bone marrow to make new white blood cells. WebGRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive … WebBoth GRANIX and a non–US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning 1 day after chemotherapy for at least 5 days Most … ptp and ptmp